Natalie Grover

Skip to main content

Author

Thomson Reuters

152 results

Future of HealthcategoryObesity fighting success fuels Novo bet on gene-editing techMay 24, 2023
United KingdomcategoryBritain draws up blueprint for multi-billion fund to back start-upsMay 11, 2023
Future of HealthcategoryAfter weight loss, Alzheimer's may be next frontier for drugs like OzempicMay 8, 2023
BusinesscategoryFlying high on obesity success, Novo's appetite for deals growsMay 5, 2023
BusinesscategoryHaleon is not losing ground to cheaper rivals, says CFOMay 3, 2023
BusinesscategoryHaleon not surprised by Pfizer stake sale plans, says CFOMay 3, 2023
BusinesscategoryAstraZeneca beats estimates on strong emerging market sales as COVID wanesApril 27, 2023
BusinesscategoryAstraZeneca increases bets on China as COVID vaccine sales fadeApril 27, 2023
BusinesscategoryGSK stays strong as healthy sales beat expectationsApril 26, 2023
BusinesscategoryGSK says EU pharma legislation overhaul could trigger investment shiftApril 26, 2023
DealscategoryGSK bets $2 bln on Bellus cough drug to soothe pipeline fearsApril 18, 2023
Healthcare & PharmaceuticalscategoryGhana first to approve Oxford's malaria vaccineApril 14, 2023
WorldcategoryUkraine needs more prosthetics clinicians as war toll mountsMarch 28, 2023
BusinesscategoryAntibiotics may not help survival of patients hospitalized with viral infections -studyMarch 24, 2023
BusinesscategoryNovo Nordisk suspended from UK lobby groupMarch 16, 2023
WorldcategoryNew tax credit scheme a lifeline for British biotech, say execsMarch 15, 2023
WorldcategorySVB shock could have chilling effect on British biotech sectorMarch 13, 2023
Healthcare & PharmaceuticalscategoryNovo obesity drug to launch in the UK soon, says watchdogMarch 8, 2023
WorldcategoryThousands of people in Ukraine have complex war-related injuries, says WHOMarch 7, 2023
BusinesscategoryViatris warns it will stop selling essential drugs in UK without changes to drug pricing agreementMarch 2, 2023

1 to 20 of 152